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Stratiﬁed treatmentSensory proﬁles are heterogeneous in neuropathic pain disorders, and subgroups of patients respond
differently to treatment. To further explore this, patients in the COMBO-DN study were prospectively
assessed by the Neuropathic Pain Symptom Inventory (NPSI) at baseline, after initial 8-week therapy with
either duloxetine or pregabalin, and after subsequent 8-week combination/high-dose therapy. Explor-
atory post hoc cluster analyses were performed to identify and characterize potential subgroups through
their scores in the NPSI items. In patients not responding to initial 60 mg/d duloxetine, adding 300 mg/d
pregabalin for combination treatment was particularly effective regarding the dimensions pressing pain
and evoked pain, whereas maximizing the duloxetine dose to 120 mg/d appeared more beneﬁcial regard-
ing paresthesia/dysesthesia. In contrast, adding 60 mg/d duloxetine to 300 mg/d pregabalin in case of
nonresponse to initial pregabalin led to numerically higher decreases in all NPSI dimensions/items com-
pared to maximizing the pregabalin dose to 600 mg/d. Cluster analysis revealed 3 patient clusters
(deﬁned by baseline scores for the 10 NPSI sensory items) with different pain proﬁles, not only in terms
of overall pain severity, but also across NPSI items. Mean Brief Pain Inventory average pain improved in
all clusters during combination/high-dose therapy. However, in patients with severe pain, the treatment
effect showed a trend in favor of high-dose monotherapy, whereas combination therapy appeared to be
2172 D. Bouhassira et al. / PAIN

155 (2014) 2171–2179more beneﬁcial in patients with moderate and mild pain (not signiﬁcant). These complementary
exploratory analyses further endorse the idea that sensory phenotyping might lead to a more stratiﬁed
treatment and potentially to personalized pain therapy.
 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).1. Introduction
Neuropathic pain is one of the most frequent complications of
diabetes [1,23,24], and, like other neuropathic pain conditions, it
is particularly difﬁcult to treat [11,19]. Evidence suggests that in
painful diabetic neuropathy, only a few drugs achieve greater than
30% reduction in pain in more than 50% of patients [21,22,26,28].
Combination therapy has been pursued to optimize clinical
outcomes [16]. Even though the COmbination vs Monotherapy of
pregaBalin and dulOxetine in Diabetic Neuropathy Study
(COMBO-DN study), a large, multinational combination treatment
trial investigating duloxetine in combination with pregabalin in
painful diabetic neuropathy [25], indicated that such a combina-
tion therapy might be a reasonable clinical option, the study failed
to meet its primary objective. One major reason accounting for
these inconclusive outcomes may be related to the fact that the
heterogeneity of neuropathic pain syndromes was not sufﬁciently
considered [2,6].
To better assess neuropathic pain in clinical practice, validated
patient-reported outcome measures such as painDETECT [14], the
Neuropathic Pain Symptom Inventory (NPSI) [10], the Neuropathic
Pain Scale (NPS) [9], or the Short-Form McGill Pain Questionnaire 2
[12] allow the assessment of both, spontaneous and evoked pains.
However, only the NPSI, NPS, and the Short-Form McGill Pain
Questionnaire 2 have been shown to be sensitive to the effects of
treatment in patients with neuropathic pain [8].
Based on these data, it was suggested that approaches relying
on a comprehensive symptomatic assessment of patients with
neuropathic pain could be more sensitive than an overall assess-
ment of pain in demonstrating and characterizing the effects of a
given pharmacological treatment [15,17]. Consistent with this
hypothesis, some studies showed that lidocaine and morphine
act differently on the different neuropathic pain symptoms and
dimensions assessed with quantitative sensory testing (QST) and/
or speciﬁc neuropathic pain questionnaires [2,3–5]. This hypothe-
sis also is supported by a recently published phase 2 study showing
that AZDD2423, a novel chemokine receptor 2 antagonist, did not
induce signiﬁcant effects on overall pain intensity, but showed
trends toward a greater reduction on the NPSI total score and NPSI
dimensions for paroxysmal pain and paresthesia/dysesthesia than
placebo [18].
The main objective of the present investigation was to further
explore these hypotheses on the basis of complementary and
exploratory analyses of data from the COMBO-DN study [25].
Neuropathic pain symptoms were prospectively assessed using
NPSI, which was a pre-speciﬁed secondary outcome measure. In
these exploratory analyses, we further compared the effects of
duloxetine and pregabalin, administered alone or in combination,
on the different dimensions of neuropathic pain.
2. Methods
Data from the multinational, randomized, double-blind, paral-
lel-group COMBO-DN study in patients with diabetic peripheral
neuropathic pain were used in the presented research. Full details
of the patients included in the study and the study design are
described by Tesfaye et al. [25].In brief, the study consisted of 2 main treatment periods of
8 weeks each: the initial therapy period and the combination/
high-dose therapy period. Patients were randomized to receive
either 60 mg duloxetine or 300 mg pregabalin during the initial
therapy period. Thereafter, patients with a <30% improvement in
the Brief Pain Inventory (BPI) 24-hour average pain score were
considered ‘‘nonresponders’’ and received double-blind treatment
for another 8 weeks during the combination/high-dose therapy
period, either as high-dose monotherapy (120 mg duloxetine for
patients previously treated with duloxetine, 600 mg pregabalin
for patients previously treated with pregabalin) or as combination
therapy (60 mg duloxetine plus 300 mg pregabalin).
As part of the secondary efﬁcacy variables of the study, the NPSI
was prospectively assessed at baseline and every 4 weeks during
the 2 therapy periods. The NPSI is a self-rated questionnaire that
includes 10 items corresponding to sensory descriptors (each rated
on a numeric scale from 0 to 10), which can be grouped into 5
dimensions (burning pain, paroxysmal pain, pressing pain, evoked
pain, paresthesia/dysesthesia), and 2 temporal items assessing
pain duration and the number of pain paroxysms. Questions
related to the 10 pain descriptors referred to the past 24 hours,
and symptoms were rated on an 11-point numeric rating scale
anchored by 0 = ‘‘no symptom’’ and 10 = ‘‘worst symptom imagin-
able.’’ Spontaneous pain during the past 24 hours (item 4) was
assessed on a 5-point categorical scale (1 = ‘‘permanently,’’
2 = ‘‘between 8 and 12 hours,’’ 3 = ‘‘between 4 and 7 hours,’’
4 = ‘‘between 1 and 3 hours,’’ 5 = ‘‘less than 1 hour’’). For the num-
ber of attacks during the past 24 hours (item 7), another speciﬁc
5-point categorical scale (1 = ‘‘more than 20,’’ 2 = ‘‘between 11
and 20,’’ 3 = ‘‘between 6 and 10,’’ 4 = ‘‘between 1 and 5,’’ 5 = ‘‘no
pain attack’’) was used. Thus, in addition to a total score, corre-
sponding to the sum of the scores of the 10 sensory descriptors,
it is possible to calculate 5 subscores corresponding to the 5
dimensions [10].
In a ﬁrst step, the study population of the COMBO-DN study was
characterized in terms of its NPSI outcomes at the beginning and
end of the initial and combination/high-dose therapy periods. Esti-
mates for treatment differences during the initial therapy period
(duloxetine vs pregabalin) and the combination/high-dose therapy
period (combination vs high-dose monotherapy) and associated
95% conﬁdence intervals are displayed graphically for NPSI scores
as well as the BPI 24-hour average pain score. NPSI outcomes at
the end of the combination/high-dose therapy period were also
examined in subgroups by initial treatment.
Then, to identify potential groups of responders to the different
treatments and to characterize them through their scores of the
different NPSI items, exploratory, post-hoc cluster analyses were
performed. Baseline scores for the 10 sensory NPSI items were
used to identify clusters of patients with similar outcomes. Clusters
were formed using Ward’s method and the cluster procedure
(PROC CLUSTER) of SAS software (SAS Institute Inc, Cary, NC).
Two cluster analyses were performed:
1. In a ﬁrst cluster analysis, the aim was to obtain clusters of high
homogeneity within cluster that are deﬁned by distinct NPSI
severity characteristics led to 7 different clusters (clusters
1–7). The only 2 clusters of a size that was considered large
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allow meaningful further analyses and interpretation were then
assessed with regard to the change in BPI average pain during
the combination/high-dose period; baseline and endpoint mean
values were graphically displayed by treatment group stratiﬁed
by initial treatment.
2. Because the sizes of the 7 clusters identiﬁed in the ﬁrst
approach varied considerably (from 48 to 184 patients) and
only 2 clusters would allow meaningful further analyses, a sec-
ond cluster analysis with 3 clusters (clusters I, II, and III) was
performed. The resulting 3 clusters were then characterized
and descriptively compared with regard to the following:
 Baseline characteristics (age, gender, weight, body mass
index, current alcohol consumption, time since diabetes
diagnosis, hemoglobin A1c, time since neuropathy diagno-
sis, time since neuropathic pain onset, and NPSI scores).
 Mean BPI 24-hour average pain score during the initial ther-
apy period, by treatment group (duloxetine vs pregabalin).
 Treatment effect (duloxetine vs pregabalin) at the end of
initial therapy on NPSI section scores and items.
 Mean BPI 24-hour average pain score during the combina-
tion/high-dose therapy period, by treatment group (combi-
nation vs monotherapy).
 Treatment effect (combination vs monotherapy) at the
end of combination/high-dose therapy on NPSI dimension
scores and items.
Treatment effects within each cluster were tested using an
analysis of covariance model with terms for baseline score (BPI
24-hour average or NPSI dimension/item score, respectively), cluster,
site, treatment (duloxetine vs pregabalin in initial therapy period;
combination therapy vs high-dose monotherapy in combination/
high-dose therapy period), and treatment by cluster interaction.
Analyses were generated using SAS software.Table 1
NPSI scores at baseline.
NPSI item Initial therapya
Duloxetine
(N = 401)
Preg
(N =
N Mean (SD) N
Total score 399 47.3 (19.16) 397
Burning pain dimension 401 5.9 (2.74) 402
Item 1: Does your pain feel like burning? 401 5.9 (2.74) 402
Pressing pain dimension 400 4.6 (2.62) 401
Item 2: Does your pain feel like squeezing? 400 4.4 (2.90) 402
Item 3: Does your pain feel like pressure? 400 4.7 (2.85) 402
Paroxysmal pain dimension 400 4.7 (2.58) 402
Item 5: Does your pain feel like electric shocks? 400 4.8 (3.11) 402
Item 6: Does your pain feel like stabbing? 401 4.6 (2.99) 403
Evoked pain dimension 400 3.7 (2.49) 399
Item 8: Pain increased by brushing? 400 3.8 (3.06) 402
Item 9: Pain increased by pressure? 401 4.2 (3.02) 403
Item 10: Pain increased by cold? 400 3.1 (2.95) 399
Paresthesia/dysesthesia dimension 400 5.9 (2.43) 403
Item 11: Do you feel pins and needles? 401 5.8 (2.74) 403
Item 12: Do you feel tingling? 400 5.9 (2.71) 403
Additional separate items related to the past 24 h
Item 4: Spontaneous pain during past 24 h 400 2.2 (1.19) 401
Item 7: Number of pain attacks during the past 24 h 401 2.9 (1.18) 399
Abbreviations: N, number of evaluable patients; NPSI, Neuropathic Pain Symptom Inven
Pain severity was rated on an 11-point numeric rating scale (from 0 = ‘‘no symptom’’ to 1
4) was assessed on a 5-point categorical scale (1 = ‘‘permanently,’’ 2 = ‘‘between 8 and 1
1 hour’’), and for the number of pain attacks during the past 24 hours (item 7) anothe
3 = ‘‘between 6 and 10,’’ 4 = ‘‘between 1 and 5,’’, 5 = ‘‘no pain attack’’) was used.
a Baseline refers to visit 2, before start of any study drug.
b Baseline refers to visit 5, before start of combination/high-dose therapy.2.1. Role of the funding source
The sponsor, Eli Lilly & Company (Indianapolis, IN), was
involved in study design, in the collection, analysis, and interpreta-
tion of data, in the writing of the manuscript, and in the decision to
submit the paper for publication.
3. Results
3.1. Baseline characteristics
A total of 804 patients of the initial therapy period and 339
patients of the combination/high-dose therapy period were evalu-
able in the analyses based on the NPSI data presented here. Demo-
graphics are summarized in the primary article that was recently
published [25]. Mean baseline values for each NPSI item, dimen-
sion score, and the total score were comparable between treatment
groups of either therapy period (Table 1).
3.2. Effects of treatments on neuropathic pain components
Consistent with other secondary efﬁcacy measures of the study
[25], the results regarding the NPSI dimensions and individual
items showed a clear trend in favor of duloxetine during the initial
therapy period. Treatment differences were statistically signiﬁcant
for all dimensions and items with the exception of the evoked pain
dimension score and 2 of its 3 items (ie, pain increased by pressure,
pain increased by cold) (Fig. 1A). During the combination/high-dose
therapy period, all treatment differences were in favor of the com-
bination therapy, but did not reach statistical signiﬁcance (Fig. 1B).
In patients who received 60 mg duloxetine as initial treatment
(Fig. 2, top) and then added 300 mg pregabalin (combination [light
gray columns]), a larger decrease in the intensity of 2 NPSI dimen-
sions (pressing pain, evoked pain) and several items (squeezing,Combination/high-dose therapyb
abalin
403)
Combination therapy
(N = 169)
High-dose monotherapy
(N = 170)
Mean (SD) N Mean (SD) N Mean (SD)
47.7 (20.46) 169 39.4 (17.96) 170 39.4 (19.91)
6.0 (2.63) 169 4.7 (2.56) 170 4.8 (2.54)
6.0 (2.63) 169 4.7 (2.56) 170 4.8 (2.54)
4.5 (2.71) 169 4.0 (2.26) 170 3.6 (2.56)
4.5 (2.97) 169 4.0 (2.55) 170 3.4 (2.71)
4.6 (2.90) 169 3.9 (2.42) 170 3.8 (2.69)
4.6 (2.68) 169 3.6 (2.18) 170 3.7 (2.48)
4.5 (3.03) 169 3.5 (2.54) 170 3.8 (2.87)
4.7 (3.12) 169 3.7 (2.48) 170 3.6 (2.76)
4.0 (2.56) 169 3.4 (2.22) 170 3.3 (2.32)
4.1 (3.03) 169 3.4 (2.46) 170 3.4 (2.63)
4.6 (2.90) 169 3.8 (2.44) 170 3.6 (2.64)
3.4 (3.03) 169 3.0 (2.67) 170 3.0 (2.62)
5.8 (2.47) 169 4.7 (2.24) 170 5.0 (2.52)
5.7 (2.79) 169 4.6 (2.37) 171 4.8 (2.76)
5.9 (2.70) 169 4.9 (2.44) 170 5.2 (2.59)
2.3 (1.18) 168 2.9 (1.24) 170 2.9 (1.31)
2.9 (1.14) 168 3.4 (1.06) 168 3.3 (1.15)
tory; SD, standard deviation.
0 = ‘‘worst symptom imaginable’’). Spontaneous pain during the past 24 hours (item
2 hours,’’ 3 = ‘‘between 4 and 7 hours,’’ 4 = ‘‘between 1 and 3 hours,’’ 5 = ‘‘less than
r speciﬁc 5-point categorical scale (1 = ‘‘more than 20,’’ 2 = ‘‘between 11 and 20,’’
-1,0 -0,8 -0,6 -0,4 -0,2 0,0 0,2 0,4 0,6
in favor of high-dose monotherapyin favor of combinaon therapy
-1,4 -1,2 -1,0 -0,8 -0,6 -0,4 -0,2 0,0 0,2 0,4 0,6
in favor of pregabalinin favor of duloxene
A: Inial Therapy
BPI 24-hour average pain
Burning pain secon
Pressing pain secon
Paroxysmal pain secon
Evoked pain secon
Paresthesia/Dysesthesia secon
Item 1: Pain feels like burning?
Item 2: Pain feels like squeezing? a
Item 3: Pain feels like pressure?
Item 4: Spontaneous pain (past 24 h) b
Item 5: Pain feels like electric shocks?
Item 6: Pain feels like stabbing?
Item 7: Number of pain aacks (past 24 h) b
Item 8: Pain increasedby brushing?
Item 9: Pain increased by pressure?
Item 10: Pain increased by cold?
Item 11: Do you feel pins and needles?
Item 12: Do you feel ngling?
B: Combinaon/High-dose Therapy
Fig. 1. Treatment effects in changes of BPI average pain and NPSI at the end of initial therapy (Visit 5) and end of combination/high-dose therapy (visit 8) cluster. (a)
Algorithm did not converge for the initial treatment data due to inﬁnite likelihood for both unstructured and autoregressive covariance matrixes. (b) Signs were reversed for
consistency across all items. Note: diamond symbol denotes the least square mean for the difference between duloxetine and pregabalin in the initial therapy period and
combination therapy and high-dose monotherapy in the combination/high-dose therapy period; the horizontal line denotes the associated 95% conﬁdence interval. BPI, Brief
Pain Inventory; NPSI, Neuropathic Pain Symptom Inventory.
2174 D. Bouhassira et al. / PAIN

155 (2014) 2171–2179pressure, pain increased by brushing, pain increase by pressure)
was seen compared with patients who maximized their duloxetine
dose (high-dose monotherapy [dark gray columns]). In contrast,
improvements in the paresthesia/dysesthesia dimension score
and its 2 items (feel ‘‘pins and needles,’’ feel tingling) were larger
in the high-dose monotherapy group. In patients who received
300 mg pregabalin during the initial therapy period (Fig. 2,
bottom), changes in the NPSI scores were consistently larger in
the combination therapy group than in the high-dose mono-
therapy group, but between-therapy differences were less
pronounced compared with those in the subgroup of patients
who received duloxetine as initial therapy.
3.3. Cluster analyses
Using the 10 sensory items of the NPSI, 7 clusters of patients
could be identiﬁed (data not shown). Cluster sizes varied between
48 (6.3% of analyzed patients) and 184 patients (22.1%). In some of
these 7 clusters, the baseline NPSI scores were relatively consistent
across all items, whereas in others there were large differences
between the intensities of the different symptoms. Because only
the cluster size of 2 clusters of the 7-cluster approach was large
enough to allow further examination of characteristics within clus-
ters and by treatment group, a new cluster analysis was performed
in which the number of clusters was set to 3.
In this second analysis, the 3 identiﬁed clusters (clusters I, II,
and III) included 232, 280, and 278 patients, respectively. Baseline
characteristics per cluster are summarized in Table 2, and baseline
scores per NPSI sensory item are depicted in Fig. 3. Mean BPI aver-
age pain was numerically higher in cluster I (7.0) than in clusters II
and III, where mean values were similar (5.9 and 5.2, respectively)
(Table 2). In cluster I, patients on average reported high intensity
(P6) for all NPSI items and dimensions, whereas patients in cluster
II had high intensity burning pain and paresthesia/dysesthesia, and
moderate or mild intensity for the other dimensions (pressing, par-
oxysmal, and evoked pain). Patients in cluster III on average had
moderate burning pain and paresthesia/dysesthesia, and mild or
no (<2) evoked, paroxysmal, and pressing pain.
Mean BPI average pain had decreased at the end of the initial
therapy period in all 3 clusters (Fig. 4), with generally higherdecreases seen for patients treated with duloxetine compared to
patients treated with pregabalin. The treatment effect was statisti-
cally signiﬁcant in clusters II (P = .020) and III (P = .002). In cluster
II, the difference between the 2 treatments was already present at
week 4, whereas in clusters I and III, corresponding differences at
week 4 were small (Fig. 4). At the end of the combination/high-
dose therapy period, there was a trend for a larger decrease in
the high-dose monotherapy group than in the combination ther-
apy group in cluster I, whereas in the other 2 clusters the improve-
ments were larger in the combination therapy group than in the
monotherapy group. However, none of these differences were
statistically signiﬁcant (Fig. 4).
4. Discussion
The present exploratory analyses of data collected in the
COMBO-DN study suggest that duloxetine and pregabalin have dif-
ferent effects on distinct neuropathic pain components in diabetic
peripheral neuropathy. Furthermore, subgroups of patients
responded differently to the administration of these 2 drugs when
given alone or in combination. These results from a prospective
evaluation of pain symptoms in a large number of patients with
the same neuropathic pain etiology as well as from post-hoc clus-
ter analyses tend to conﬁrm the advantages of sensory phenotyp-
ing in clinical trials, as suggested by others [2,6,27]. Our results
also add to the knowledge base regarding sensory proﬁles in neu-
ropathic pain conditions, and further support the predictive value
of a thorough baseline assessment as shown in exploratory post
hoc analyses of placebo-controlled trials [13] and cross-sectional
cohort surveys [7,20].
As previously reported [25], the superior analgesic efﬁcacy
(based on the change in overall BPI 24-hour average pain) of
60 mg/d duloxetine for initial pain treatment was also reﬂected
by greater effects on the different NPSI dimensions, with the
exception of the evoked pain dimension. Interestingly, when
examining the changes in the dimensions more closely, and when
comparing the maximum doses of both drugs with their ﬁxed
combination of 60 mg/d duloxetine plus 300 mg/d pregabalin in
the combination/high-dose therapy period, our data also indicated
different effects of the drugs, depending on the pain dimension.
-2,2
-2
-1,8
-1,6
-1,4
-1,2
-1
-0,8
-0,6
-0,4
-0,2
0
Me
an
 sc
or
e (
st
an
da
rd
 er
ro
r)
60 mg duloxetine added (high-dose monotherapy) (N=73)
300 mg pregabalin added (combination therapy) (N=75)
Inial therapy with 
60 mg duloxene
-2,2
-2
-1,8
-1,6
-1,4
-1,2
-1
-0,8
-0,6
-0,4
-0,2
0
Me
an
 sc
or
e (
st
an
da
rd
 er
ro
r)
300 mg pregabalin added (high-dose monotherapy) (N=97)
60 mg duloxetine added (combination therapy) (N=94)
Inial therapy with 
300 mg pregabalin
Fig. 2. Change in NPSI subscores and items at end of combination/high-dose therapy (visit 8) (last observation carried forward). (Top) Duloxetine as initial treatment.
(Bottom) Pregabalin as initial treatment. N, total number of patients; NPSI, Neuropathic Pain Symptom Inventory. aFor these items (items 4 and 7) signs were reversed for
consistency with other NPSI scores.
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to an initial treatment with duloxetine alone was particularly ben-
eﬁcial on the evoked pain and pressing pain dimensions, whereas
the feeling of abnormal sensations in the painful area as assessed
by the paresthesia/dysesthesia dimension appeared to be more
susceptible to maximizing the dosage of duloxetine. In contrast,
combining duloxetine with pregabalin in patients not responding
to pregabalin alone induced a more homogenous decrease in the
different neuropathic pain components, which was slightly larger
than for patients treated with high-dose pregabalin. In principle,
it would have been important to conﬁrm the differential effects
of the 2 drugs by directly comparing the effects of duloxetine
and pregabalin at their maximum recommended doses. However,
this was not feasible in our study because of the design, in which
patients with P30% improvement in pain were considered
‘‘responders’’ to the initial treatment and were not included in
the combination/high-dose therapy period of the study. In anycase, these ﬁndings based on post-hoc analyses warrant further
research with a prospective sensory phenotyping of the patients.
Our ﬁndings also indicate that neither 60 mg/d nor 120 mg/d of
duloxetine should be regarded as similar ‘‘monotherapies’’ when
compared with 300 mg/d and 600 mg/d of pregabalin, respectively.
Consequently, pooling the data from the 2 high-dose monotherapy
regimens for the comparison with the combination regimen may
have biased the interpretation of the results and the main conclu-
sions of the COMBO-DN study reported previously [25].
On one hand, our cluster analyses provide support for differen-
tial effects of duloxetine and pregabalin. On the other hand, the
lack of signiﬁcant differences between combination therapy and
monotherapy in the 3 clusters, which is consistent with the conclu-
sion in the paper summarizing the main study results [25], tends to
contradict our hypothesis that the combination may have been
more beneﬁcial in a speciﬁc subgroup of patients. The notable dif-
ferences among the 3 clusters that were identiﬁed on the basis of
Table 2
Baseline characteristics per cluster.
Variable Cluster I (N = 232) Cluster II (N = 280) Cluster III (N = 278)
N Statistic N Statistic N Statistic
Age. years, mean (SD) 232 59.7 (11.02) 280 61.1 (10.77) 278 64.0 (10.24)
P65 years, n (%) 77 (33.2) 102 (36.4) 129 (46.4)
Male, n (%) 232 120 (51.7) 280 152 (54.3) 278 170 (61.2)
Weight, kg, mean (SD) 232 85.4 (21.74) 280 87.0 (17.98) 277 84.9 (18.97)
BMI, kg/m2, mean (SD) 231 31.0 (6.58) 280 31.2 (5.87) 277 30.1 (5.70)
Current alcohol consumption, n (%) 232 52 (22.4) 280 89 (31.8) 278 85 (30.6)
Time since diabetes diagnosis, years, median (Q1, Q3) 232 11.7(7.2, 19.8) 280 10.5(5.9, 17.5) 278 10.7 (5.9, 19.7)
HbA1c, %, mean (SD) 232 8.2 (1.70) 279 7.9 (1.67) 277 7.7 (1.51)
Time since neuropathy diagnosis, years, median (Q1, Q3) 232 2.2 (0.8, 5.6) 280 2.3 (1.0, 4.8) 278 2.1 (0.7, 4.8)
Time since neuropathic pain onset, years, median (Q1, Q3) 232 1.6 (0.7, 5.3) 280 1.9 (0.8, 4.1) 278 2.1 (0.8, 4.0)
No prior DPNP therapy, n (%) 232 135 (58.2) 280 195 (69.6) 278 194 (69.8)
BPI 24-h average pain, mean (SD) 232 7.0 (1.43) 279 5.9 (1.35) 277 5.2 (1.35)
NPSI score, mean (SD)
Total score 232 69.9 (11.75) 280 48.7 (7.84) 278 27.6 (11.02)
Burning pain dimension 232 7.3 (2.29) 280 6.3 (2.09) 278 4.4 (2.76)
Pressing pain dimension 232 6.6 (2.26) 280 5.0 (1.78) 278 2.3 (2.04)
Paroxysmal pain dimension 232 7.1 (1.60) 280 5.0 (1.79) 278 2.3 (1.85)
Evoked pain dimension 232 6.5 (1.64) 280 3.4 (1.85) 278 2.1 (1.76)
Paresthesia/dysesthesia dimension 232 7.8 (1.39) 280 6.1 (1.90) 278 3.9 (2.26)
Temporal items
Item 4: Spontaneous pain during past 24 h 232 1.8 (0.96) 280 2.4 (1.06) 278 2.5 (1.36)
Item 7: Number of pain attacks during past 24 h 232 2.3 (0.99) 280 2.8 (1.02) 278 3.5 (1.13)
Abbreviations: BMI, body mass index; DPNP, diabetic peripheral neuropathic pain; HbA1c, hemoglobin A1c; N, number of patients with available data; n, number of patients
with characteristic; NPSI, Neuropathic Pain Symptom Inventory; Q1, ﬁrst quartile; Q3, third quartile; SD, standard deviation.
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sensory abnormalities differed across patients. These data are con-
sistent with those of previous studies showing the heterogeneity of
neuropathic pain in patients whose pain was assessed with the
painDETECT [7] or the NPSI [13]. The response to the initial treat-
ment was similar in the 3 patient clusters, with 60 mg duloxetine
resulting in a higher decrease in overall pain intensity than 300 mg
pregabalin. Between-treatment differences within cluster were
statistically signiﬁcant in 2 of the 3 clusters.
Taken together, our data are in line with suggestions that the
heterogeneity of neuropathic pain syndromes should be taken into
account in the consideration of treatment strategies [2,6,13,29],
despite the lack of a clear difference in the clusters regarding the
comparison between combination and monotherapy. Several stud-
ies using QST showed that some drugs (eg, lidocaine, morphine,
botulinum toxin) have a preferential action on some neuropathicsymptoms, suggesting that symptoms or combinations of symp-
toms depend on different mechanisms [13,20]. Thus, our data con-
ﬁrming the heterogeneity of patients within a single etiology tend
to support that grouping patients based on sensory symptoms and
signs rather than on etiology may be a meaningful way to improve
response to pharmacological treatment [13]. However, further sci-
entiﬁc evidence is needed to support these encouraging ﬁndings in
patients with diabetic peripheral neuropathic pain. Moreover, the
present results should be conﬁrmed in prospective studies in
different subgroups of patients with pain due to other etiologies.
From a practical point of view, these exploratory data suggest
that patients with painful diabetic neuropathy in whom insufﬁ-
cient pain relief is obtained after 8-week treatment with 60 mg/d
duloxetine might beneﬁt from combination treatment by adding
300 mg/d pregabalin, particularly if they present with a high inten-
sity of pressing pain and evoked pain. In contrast, maximizing the
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option when paresthesia/dysesthesia is the main issue For initial
pregabalin nonresponders, increasing the pregabalin dose to
600 mg/d or combination treatment with 60 mg/d duloxetine
might both be reasonable clinical options. However, our tentative
practical conclusions should be regarded with caution, because
several limitations should be considered with regard to the inter-
pretation of our data. First, treatment response to duloxetine, pre-
gabalin, or their combination does not entirely depend on sensory
phenotypes. Other factors inﬂuencing drug metabolism and sus-
ceptibility, including psychological trait and state variables or prior
treatment experiences, should be taken into account. Second, the
lack of a placebo group is an important drawback, because it can-
not be excluded that some of the differences reported here were
not speciﬁc. In particular, one cannot exclude that nonspeciﬁc pla-
cebo effects contributed to the reduction of the difference between
responders and nonresponders or masked relevant sensory proﬁles
in our patients. Another potential limitation is that our analyses
were exploratory and no formal correction was applied for
multiple testing. However, it should be noted that lowering thesigniﬁcance threshold and thus decreasing the risk of type I error
by such correction methods also leads to a large increase of the
likelihood of type II errors [22]. We aimed to avoid the risk of
false-negative results and, despite lack of correction, consider our
ﬁndings of importance to generate new working hypotheses and
to adequately power future studies related to this topic. Finally,
it should be kept in mind that there are also some limitations
related to cluster analyses: as there are no objective and compelled
rules for determination of an optimal cluster number, the attempt
to obtain clusters of high homogeneity and practical decisions
regarding minimal group numbers have inﬂuenced the choice of
the number of clusters.
4.1. Conclusion
The present exploratory analyses further support the hypothe-
sis that variability in sensory proﬁles exists across patients with
diabetic peripheral neuropathic pain. In essence, the identiﬁcation
of subgroups of patients with distinct pain characteristics at base-
line and their differential responses to duloxetine and pregabalin,
2178 D. Bouhassira et al. / PAIN

155 (2014) 2171–2179alone or in combination, is encouraging, and indicates that hetero-
geneity in the patient population should be taken into account for a
more stratiﬁed or even personalized treatment approach.
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